O objetivo do presente estudo foi avaliar preliminarmente a eficácia do grupo terapêutico de abordagem gestáltica no tratamento do Transtorno Depressivo Recorrente através da avaliação quantitativa dos sintomas depressivos, avaliação da qualidade de vida e adequação social. Foi um estudo aberto, exploratório, prospectivo, em pacientes que se encontravam em tratamento farmacológico para Transtorno Depressivo Recorrente, submetidos a dezesseis sessões de grupo terapêutico. Aplicou--se no início e no fim do tratamento: Entrevista Clínica Estruturada para o DSM-IV: Transtorno do Eixo I, 17-item Hamilton Depression Rating Scale, Medical Outcomes Study 36-item Short-Form Health Survey e Escala de Auto-Avaliação de Adequação Social. Sete pacientes terminaram as dezesseis semanas de tratamento. Observou-se melhora clínica em relação aos sintomas depressivos. Em relação à qualidade de vida, apresentaram melhora nos domínios da capacidade funcional; estado geral da saúde; saúde mental e dor. Perceberam-se inadequados em relação à adequação social, porém apresentaram indicadores clínicos de melhora após grupo terapêutico. Resultados sugerem que a participação no grupo terapêutico de abordagem gestáltica pode auxiliar na redução da sintomatologia depressiva, em certos domínios da qualidade de vida e em ganhos clínicos. Estudos com amostras maiores, com grupo controle e com melhor avaliação da adequação social e funcionalidade dos pacientes são necessários / The intention of this study was to make a preliminarily evaluation of the effectiveness of gestalt group therapy in the treatment of major depression through the quantitative assessment of the symptoms of depression and an assessment of quality of life and social functioning. The open study was of an exploratory nature and involved patients who were undergoing pharmacological treatment for major depression and who participated in sixteen gestalt group therapy sessions. The effectiveness of the therapeutic process was assessed by Structured Clinical Interviews at the beginning and at the end of treatment at which were applied the DSM-IV: Disorder Axis I, 17-item Hamilton Depression Rating Scale, Medical Outcomes Study 36-item Short-Form Health Survey Scale and Self-Assessment of Social Adequacy. Seven patients completed the sixteen weeks of treatment. A clinical improvement in the depressive symptoms was observed. With regard to quality of life, the patients showed improvement in their physical functioning, general health, mental health and bodily pain. They considered themselves poorly adjusted to society and presented improved clinical indicators after group therapy. The results suggest that participation in gestalt group therapy can help reduce the symptoms of depression, improve some areas of quality of life and demonstrate clinical gains. Further studies with a larger sample, the use of a control group and improved assessment methods of social adequacy and functionality are needed

Background: The aim of this thesis was to investigate the relationship of moral cognition and emotions to the pathophysiology of major depressive disorder (MDD). Patients with MDD may experience excessive guilt or self-blaming biases despite recovery from the depressed state. Since guilt is a moral emotion thought to motivate altruistic behaviours, it has been hypothesized that elevated self-blame in MDD may result in pathological increases to altruism in some patients. The relationship of self-blame to altruistic choices in individuals with remitted MDD (rMDD), however, has not been established. Guilt has been shown to activate the subgenual cingulate and adjacent septal region (SCSR) which is of known importance to the pathophysiology of MDD. Since MDD is thought to arise from network-level dysfunctions, and moral cognition and emotions are hypothesized to emerge from network-level binding, investigating resting-state SCSR functional connectivity in rMDD patients and healthy control (HC) participants could reveal networks of potential relevance both to MDD and to moral cognition and emotions. Chapter 2: We investigated whether melancholic rMDD patients could be distinguished from non-melancholic and HC groups on the basis of resting-state functional connectivity to an SCSR seed region. Lower SCSR-amygdala connectivity distinguished the melancholic rMDD group from non-melancholic and HC groups. Chapter 3: We investigated whether patients who remained resilient to recurring depressive episodes were distinguishable from recurring episode MDD and HC groups on the basis of resting-state connectivity to an SCSR seed region. Lower interhemispheric SCSR connectivity distinguished the resilient MDD patients from the recurring episode MDD and HC groups. Chapter 4: We measured explicit and implicit preferences for social options with and without altruistic motivations relative to selfish options in the rMDD and HC groups during emotion priming to modulate feelings of guilt. The rMDD patients explicitly preferred prosocial options (i.e., social options and altruism directed towards friends or colleagues) less than HC participants. Regardless of group, guilt priming increased explicit and implicit preferences for altruism towards strangers. Chapter 5: We investigated whether explicit and/or implicit preferences for prosocial options during guilt priming were correlated with resting-state connectivity to an SCSR seed region, and whether this relationship could distinguish the rMDD and HC groups. Across all participants, implicit prosocial choice preference negatively correlated with connectivity between the SCSR and right temporoparietal junction (TPJ). The relationship of SCSR-TPJ connectivity to implicit preferences for social options and for altruism towards friends and colleagues was weaker in the rMDD group compared to the HC group, particularly for implicit altruism. Conclusions: We identified resting-state SCSR networks associated with vulnerability to melancholia and with resilience to recurring depressive episodes. Patients with rMDD explicitly preferred options entailing social withdrawal, a symptom associated with MDD vulnerability. Irrespective of group, guilt motivated altruism towards strangers but not friends and colleagues. Implicit prosociality was negatively associated with connectivity in a social agency network, and the comparatively weak relationships between connectivity and implicit choice preferences in rMDD patients may reflect a vulnerability factor for MDD.

O Transtorno Depressivo Maior (TDM) é uma condição psiquiátrica que afeta 4,4% da população mundial, exibindo um substancial sofrimento pessoal, incapacidade e custos sociais, e estima-se que ele será a principal causa de incapacidade no mundo em 2030. O surgimento de novas ferramentas e modelos de pesquisa envolvendo o TDM irá auxiliar no entendimento desta doença. Deste modo, o objetivo deste trabalho foi gerar uma coleção de células-tronco pluripotentes induzidas humanas (hiPSCs) de um grupo de indivíduos com TDM. Foram coletadas amostras de células mononucleares (MNCs) de 66 indivíduos afetados, e geradas 6 linhagens de hiPSCs. Através de diversos testes de caracterização, a pluripotência destas células foi confirmada. Além disto, também foi padronizada a diferenciação destas hiPSCs em neurônios serotonérgicos. Neurônios derivados dessas hiPSCs poderão constituir material de estudo para outros grupos de pesquisa interessados no estudo da TDM, e ser utilizados em testes futuros para prever resposta a medicamentos. / Major Depressive Disorder (MDD) is a psychiatric condition that affects 4.4% of the world\'s population, exhibiting substantial personal suffering, disability and social costs, and is estimated to be the leading cause of disability in the world by 2030. Emergence of new tools and research models involving TDM will aid in the understanding of this disease. Thus, the objective of this work was to generate a collection of human induced pluripotent stem cells (hiPSCs) from a group of individuals with MDD. Samples of mononuclear cells (MNCs) of 66 affected individuals were collected, and 6 lines of hiPSCs were generated. Through several characterization tests, the pluripotency of these cells was confirmed. In addition, the differentiation of these hiPSCs into serotonergic neurons was also standardized. Neurons derived from these hiPSCs could constitute study material for other research groups interested in the study of MDD, and be used in future tests to predict drug response.

No description available.

The familial aggregation of Major Depressive Disorder (MDD) has been repeatedly demonstrated. Several studies have investigated associations between various clinical characteristics of MDD in probands and overall rates of MDD in relatives. Few studies, however, have considered the familial aggregation of clinical characteristics of MDD. The aim of the present report is to examine mother–offspring associations of a variety of clinical characteristics of MDD in a general population sample. Data were derived from baseline and 4-year-follow-up data of 933 adolescents and their biological mothers of the Early Developmental Stages of Psychopathology (EDSP) study, a prospective-longitudinal community study. MDD and its characteristics were assessed with the Munich-Composite International Diagnostic Interview. We found that children of mothers who had a lifetime history of severe MDD and high number of symptoms, high impairment and/or melancholia, revealed elevated odds of MDD regarding the same characteristics as their mothers (ORs between 5.2 and 13.9). The observed associations did not differ by the children’s sex. DSM-IV melancholia and severity as well as impairment were found to aggregate within families. This finding can be interpreted as a validation of the DSM-IV MDD severity subtypes as well as of the melancholic specifier. Severe and melancholic MDD reveal a considerable high degree of familiar aggregation making the search for mechanisms involved in the familiar transmission of these forms of MDD particularly promising.

Over 16 million people in the US suffer from major depressive disorder (MDD) each year. Approximately 1/3rd of MDD patients (~5 million) obtain only partial remission or no benefit after trials with multiple drugs or drug combinations. Recently, Ordway and colleagues have reportedelevated levels of DNA oxidation and upregulated gene expression of the base excision repair enzyme poly(ADP-ribose) polymerase-1 (PARP1) in postmortem brain from donors who had MDD at the time of death, as compared to age-matched psychiatrically normal control donors. This study was designed to test whether an inhibitor of PARP, 3-aminobenzamide (3-AB), may be effective to alleviate depressive-like behaviors in a rodent model of treatment-resistant depression. Male rats were ip administered lipopolysaccharide (LPS;100ug/kg) daily for 28 days, and administered a chronic unpredictable stressor on each day. All rats were also administered saline, 3-AB (40 mg/kg), or the serotonin-reuptake inhibitor (SSRI) fluoxetine (trade name: Prozac; 10 mg/kg) on each day, approximately 30 min after LPS treatment. During the 28 day period of LPS treatment, animals were behaviorally tested 5 times on sucrose preference (a test of anhedonia). At the end of the 28 day period, rats were behaviorally tested on a test of acute stress, the Porsolt swim test. Results revealed that 3-AB alleviated anhedonia and the response to acute stress in the Porsolt swim test superior to the fluoxetine group, demonstrating the utility of a PARP inhibitor to alleviate depressive-like behavior in this model. In addition, fluoxetine produced a loss of weight which recovered over days, but not to control levels, and 3-AB did not produce this effect. This study shows that PARP inhibitors may be effective in treatment-resistant depression.

Previous research has revealed heterogeneity in outcome trajectories among individuals seeking psychotherapy. However, questions remain as to the number, nature, and predictors of these trajectories. Therefore, the present study had three aims: 1) to identify heterogeneous latent groups among treatment trajectories of 212 clients with major depressive disorder (MDD) seeking psychotherapy at a community mental health training clinic; 2) to identify significant associations between clinical and demographic variables and group membership; and 3) to identify correlations between trajectory shape and positive treatment outcome. Prior to treatment, participants provided demographic information and completed symptom severity ratings. Once in treatment, participants completed a self-report of distress via the Outcome Questionnaire (OQ-45) at every session. Growth mixture modeling was utilized to identify distinct patient subgroups based on outcome trajectories among the sample. Three distinct latent classes of treatment trajectory were identified, providing evidence of heterogeneity in treatment trajectories among individuals with MDD. Baseline distress, pre-treatment work problems, and sleep difficulties were found to be predictive of an individual's membership in a specific trajectory group. Finally, specific shapes of change, namely early response and sudden gains, were associated with positive treatment outcome. Findings from this study can be used to identify patients at risk for treatment failure, allowing clinicians to intervene earlier to enhance mid-treatment feedback and prognosis.

Although the link between androgens and depression is well established in adults, the effects of cofactors on this association are less clearly understood, particularly in youth. Epidemiological cohort study of adolescents in Dresden, Germany. Analyses comprised data of 985 individuals assessed at baseline and of 512 individuals at 1-year follow-up. We investigated multivariable regression models for cross-sectional and longitudinal associations of hair testosterone, dehydroepiandrosterone (DHEA), and their cortisol ratios with 12-month diagnoses of major depressive disorder (MDD) and MDD without any anxiety disorder assessed with standardized diagnostic interview (DIA-X-5), and with dimensional depression scores (PHQ-9, PROMIS), separately for males and females. The potential moderating effect of social support was determined. Cross-sectional analyses yielded inverse associations of testosterone and DHEA with MDD and MDD without any anxiety disorders in males. In cross-sectional and longitudinal analyses, baseline ratio cortisol/DHEA was significantly, inversely associated to PROMIS-depression in males. Only cross-sectional associations for ratio cortisol/DHEA and PROMIS-depression remained significant after Bonferroni-Holm correction. No robust associations were observed in female participants. Social support exerted no consistent moderating effect on the investigated association. The present observational cohort study showed no consistent association of hair androgen concentrations with depressive disorders in adolescents. However, findings provide some support for the association between the cortisol/DHEA ratio and depression in males. Longitudinal research designs in large samples are needed to understand the interplay between androgens, depression, and developmental and social factors in youth.

No description available.

No description available.